Cargando…

Serum levels of proteins involved in amyloid-β clearance are related to cognitive decline and neuroimaging changes in mild cognitive impairment

INTRODUCTION: Amyloid-β (Aβ) clearance is important for damage prevention in Alzheimer's disease. We investigated the utility of Aβ clearance proteins as biomarkers for mild cognitive impairment (MCI). METHODS: Serum apolipoprotein (apo) A-I, compliment protein C3 (C3), transthyretin, and chole...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Shan, Suzuki, Hideaki, Ito, Hitomi, Korenaga, Tatsumi, Akatsu, Hiroyasu, Meno, Kohji, Uchida, Kazuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Special Section: Blood-Based Biomarkers for Alzheimer's Disease & Related Dementias. (Editor: Henrik Zetterberg)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335589/ https://www.ncbi.nlm.nih.gov/pubmed/30671532 http://dx.doi.org/10.1016/j.dadm.2018.11.003

Ejemplares similares

Amyloid-β sequester proteins as blood-based biomarkers of cognitive decline
por: Uchida, Kazuhiko, et al.
Publicado: (2015)

Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition
por: Osborn, Katie E., et al.
Publicado: (2019)

Complement protein levels in plasma astrocyte-derived exosomes are abnormal in conversion from mild cognitive impairment to Alzheimer's disease dementia
por: Winston, Charisse N., et al.
Publicado: (2019)

Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals
por: Benedet, Andréa L., et al.
Publicado: (2019)

Aβ and tau structure-based biomarkers for a blood- and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer's disease
por: Nabers, Andreas, et al.
Publicado: (2019)

A proteomic signature for dementia with Lewy bodies
por: O'Bryant, Sid E., et al.
Publicado: (2019)

Posttraumatic stress disorder and total amyloid burden and amyloid-β 42/40 ratios in plasma: Results from a pilot study of World Trade Center responders
por: Clouston, Sean A.P., et al.
Publicado: (2019)

Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
por: Fossati, Silvia, et al.
Publicado: (2019)

Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study
por: O'Bryant, Sid E., et al.
Publicado: (2019)

Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition
por: Risacher, Shannon L., et al.
Publicado: (2019)

Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers
por: Rózga, Małgorzata, et al.
Publicado: (2019)

Sets of coregulated serum lipids are associated with Alzheimer's disease pathophysiology
por: Barupal, Dinesh Kumar, et al.
Publicado: (2019)

Plasma lipocalin-2 levels in the preclinical stage of Alzheimer's disease
por: Eruysal, Emily, et al.
Publicado: (2019)

Blood-based biomarkers for Alzheimer's disease and related dementias: Keys to success and things to consider
por: Zetterberg, Henrik, et al.
Publicado: (2019)

Reduced plasma desmosterol-to-cholesterol ratio and longitudinal cognitive decline in Alzheimer's disease
por: Sato, Yoshiaki, et al.
Publicado: (2015)

Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease‐related declines
por: Thomas, Kelsey R., et al.
Publicado: (2021)

A novel detection method of cleaved plasma high-molecular-weight kininogen reveals its correlation with Alzheimer's pathology and cognitive impairment
por: Yamamoto-Imoto, Hitomi, et al.
Publicado: (2018)

Elevated plasma neurofilament light in aging reflects brain white‐matter alterations but does not predict cognitive decline or Alzheimer's disease
por: Nyberg, Lars, et al.
Publicado: (2020)

Repeated systemic inflammation was associated with cognitive deficits in older Britons
por: Tampubolon, Gindo
Publicado: (2015)

Identification of plasma proteins relating to brain neurodegeneration and vascular pathology in cognitively normal individuals
por: Shi, Liu, et al.
Publicado: (2021)

Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS)
por: Li, Danni, et al.
Publicado: (2016)

Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers
por: DeMarshall, Cassandra A., et al.
Publicado: (2016)

Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile
por: Winston, Charisse N., et al.
Publicado: (2016)

The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment
por: Klavins, Kristaps, et al.
Publicado: (2015)

Prospective associations of plasma phospholipids and mild cognitive impairment/dementia among African Americans in the ARIC Neurocognitive Study
por: Li, Danni, et al.
Publicado: (2016)

Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals
por: Fandos, Noelia, et al.
Publicado: (2017)

Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia
por: van Wijk, Nick, et al.
Publicado: (2017)

Changes of plasma cGP/IGF‐1 molar ratio with age is associated with cognitive status of Parkinson disease
por: Fan, Dawei, et al.
Publicado: (2020)

A panel of blood lipids associated with cognitive performance, brain atrophy, and Alzheimer's diagnosis: A longitudinal study of elders without dementia
por: Ma, Ya‐Hui, et al.
Publicado: (2020)

Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort
por: Gonzales, Mitzi M., et al.
Publicado: (2022)

Effect of APOE ε4 allele on levels of apolipoproteins E, J, and D, and redox signature in circulating extracellular vesicles from cognitively impaired with no dementia participants converted to Alzheimer's disease
por: Ben Khedher, Mohamed Raâfet, et al.
Publicado: (2021)

Identification of Plasma Proteins as Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease Using Liquid Chromatography–Tandem Mass Spectrometry
por: Inoue, Makoto, et al.
Publicado: (2023)

Plasma BDNF levels associate with Pittsburgh Compound B binding in the brain
por: Hwang, Kristy S., et al.
Publicado: (2015)

Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology
por: Savica, Rodolfo, et al.
Publicado: (2016)

Molecular markers of neuropsychological functioning and Alzheimer's disease
por: Edwards, Melissa, et al.
Publicado: (2015)

Blood protein predictors of brain amyloid for enrichment in clinical trials?
por: Ashton, Nicholas J., et al.
Publicado: (2015)

Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges
por: O'Bryant, Sid E., et al.
Publicado: (2015)

MicroRNA deregulation and chemotaxis and phagocytosis impairment in Alzheimer's disease
por: Guedes, Joana R., et al.
Publicado: (2015)

Thrombopoietin is associated with δ's intercept, and only in Non-Hispanic Whites
por: Royall, Donald R., et al.
Publicado: (2016)

Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging
por: Gupta, Veer Bala, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_b2pqv7tt6m8905qep36val7j90